<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666016</url>
  </required_header>
  <id_info>
    <org_study_id>WN29850</org_study_id>
    <secondary_id>TRO19622 CL E Q 1159-1</secondary_id>
    <nct_id>NCT00666016</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, the tolerability and the short term effect
      on liver enzymes of TRO19622 500 mg for one month in patients with Non-Alcoholic
      Steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in ALT as assessed by an ANCOVA with the following covariates: treatment, gender, subject and time and a non parametric test (Conover-Salsburg).</measure>
    <time_frame>Mean change in ALT at V1 (Day15) and V2 (Day 30)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained reduction in ALT to either 50% of baseline or value &lt; or equal to ULN. Sustained reduction serum AST and GGT.Clinical and laboratory safety.</measure>
    <time_frame>V1 (Day 15), V2 (Day 30) and V3 (Day 60)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRO19622 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRO19622</intervention_name>
    <description>TRO19622 500 mg once a day before noon meal during 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects older than 18 years.

          -  Persistent ALT elevation (&gt; 2 times the ULN of the local laboratory of the
             investigating site) over 6 months prior to entry into study.

               -  No more than one ALT value within the normal range in the past year.

               -  Patients must have had an ALT measurement at least once every 6 months within the
                  year before inclusion.

          -  Histologically confirmed diagnosis of steatohepatitis on biopsy within 2 years prior
             to entry into protocol.

          -  Compensated liver disease with the following hematologic, biochemical, and serological
             criteria on entry into protocol:

               -  Hemoglobin &gt; 11 gm/dL for females and &gt; 12 gm/dL for males

               -  White blood cell (WBC) &gt; 2.5 K/UL

               -  Neutrophil count &gt; 1.5 K/UL

               -  Platelets &gt; 100 K/UL

               -  Total bilirubin &lt; 35 µmol/L)

               -  Albumin &gt; 36 g/L

               -  TP &gt; 80% .

               -  Serum creatinine within normal limits

          -  No other cause of chronic liver disease (autoimmune,primary biliary cirrhosis, HBV,
             Wilson, alpha-1-antitrypsin deficit, hemochromatosis etc\dots )

          -  If applicable, have a stable diabetes, defined as HbA1c &lt; 9% and fasting glycemia &lt; 10
             mmol/L,no changes in medication in the previous 6 months, and no new symptoms
             associated with diabetes in the previous 3 months.

          -  If applicable have a stable metabolic condition (diagnosis made at least 6 months
             before inclusion), without major weight or laboratory tests changes.

          -  Negative pregnancy test or post menopausal.

          -  Have an electrocardiogram (ECG) without any clinically significant abnormality.

          -  Subjects must be willing to give written informed consent.

        Exclusion Criteria:

          -  Evidence of another form of liver disease.

          -  History of excess alcohol ingestion: daily alcohol consumption &gt;30 g/day (3 drinks per
             day) for males and &gt;20 g/day (2 drinks/day) for females.

          -  Unstable metabolic condition: Weight change &gt; +/- 10% in the previous year, diabetes
             with poor glycemic control (HbA1c &gt;9%),introduction of an antidiabetic or of an
             anti-obesity drug in the past 6 months prior to screening.

          -  History of gastrointestinal bypass surgery or ingestion of drugs known to produce
             hepatic steatosis including corticosteroids,high-dose estrogens, methotrexate,
             tetracycline or amiodarone in the previous 6 months.

          -  Significant systemic or major illnesses other than liver disease,including congestive
             heart failure, coronary artery disease, cerebrovascular disease, pulmonary disease,
             renal failure, organ transplantation, serious psychiatric disease,malignancy that, in
             the opinion of the investigator would preclude treatment with TRO19622 and/or adequate
             follow up.

          -  HIV infection.

          -  Active substance abuse, such as inhaled or injection drugs within the previous year.

          -  Pregnancy or inability to practice adequate contraception in women of child-bearing
             potential.

          -  Active malignancy except cutaneous basocellular carcinoma.

          -  Any other condition which, in the opinion of the investigator would impede competence
             or compliance or possibly hinder completion of the study.

          -  Body mass index (BMI) &gt;40 kg/m2 (obesity Grade III).

          -  Type 1 diabetes or Insulin-treated type 2 diabetes.

          -  Hemostasis disorders or current treatment with anticoagulants.

          -  History of, or current cardiac dysrhythmias and / or a history of cardiovascular
             disease, including myocardial infarction, except patients with only well controlled
             hypertension.

          -  Participation in any other investigational drug or therapy study within the previous 3
             months.

          -  Be possibly dependent on the Investigator or the Sponsor (eg, including, but not
             limited to, affiliated employee).

          -  Medications that could interfere with TRO19622 absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad Ratziu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GH PITIE-SALPETRIERE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non alcoholic steatohepatitis nash hepatoprotective hepatoprotection ALT AST new drug candidate interventional study TRO19622 Trophos cholest-4-en-3-one oxime</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

